Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DYVOX.STthis companyDynavox Group AB (publ)	SEK 72.60	64.97×	17.82×	4.35×	24.44×	-107.9%	68.4%	10.3%	6.7%	27.5%	10.7%	-0.1%	1.83×	1.91×	6.12×	1.57×	0.0%	6	4.43	3	B-
EKTA-B.STElekta AB (publ)	SEK 59.45	-39.44×	2.88×	1.22×	14.61×	-44.6%	37.4%	2.6%	-3.1%	-7.3%	2.9%	11.5%	1.03×	2.46×	1.17×	0.87×	4.5%	5	1.34	2	C
SECT-B.STSectra AB (publ)	SEK 315.60	87.1×	22.99×	13.88×	60.92×	-85.4%	20.2%	18.7%	15.9%	26.4%	22.5%	2.1%	0.04×	-2.23×	0×	1.61×	0.8%	6	19.97	3	B+
TOBII.STTobii AB (publ)	SEK 0.70	-2.32×	1.29×	0.61×	3.51×	-3404.2%	23.7%	-36.3%	-26.0%	-55.2%	-26.0%	16.8%	1.52×	1.71×	-17.82×	1.14×	0.0%	4	-3.68	1	C-
VITR.STVitrolife AB (publ)	SEK 119.60	-3.7×	2.35×	5.39×	-4.41×	-125.6%	58.1%	-140.6%	-145.7%	-63.5%	-45.8%	2.5%	0.2×	-0.18×	-70.07×	3.4×	0.8%	5	1.03	2	C+
XVIVO.STXvivo Perfusion AB (publ)	SEK 200.80	233.25×	2.78×	7.24×	37.29×	-172.4%	65.7%	11.5%	3.1%	1.2%	2.7%	-2.6%	0.06×	-1.09×	2.1×	5.77×	0.0%	6	12.47	3	B-
Peer median	—	-2.32×	2.78×	5.39×	14.61×	-125.6%	37.4%	2.6%	-3.1%	-7.3%	2.7%	2.5%	0.2×	-0.18×	0×	1.61×	0.8%	5	1.34	2	—